Sensei Biotherapeutics IncFRA Sensei Stock Report

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 56 full-time employees. The company went IPO on 2021-02-04. The firm has designed two approaches to develop therapeutics its Tumor Microenvironment Activated biologics (TMAb) platform, which disables checkpoints and other immunosuppressive signals in the tumor microenvironment to unleash existing T cells against tumors, and the ImmunoPhage platform, which trains new T cells to recognize and kill malignant cells. Using its TMAb platform, the Company is developing SNS-101, human antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively only within the low pH tumor microenvironment. The firm is also using its platforms to develop other preclinical programs targeting multiple solid tumor indications. The firm has four investigational products in various stages of early development: SNS-101, SNS-102, SNS-103 and SNS-401.